Skip to main content
Erschienen in: Journal of Neuro-Oncology 3/2019

06.12.2018 | Topic Review

Use of optical fluorescence agents during surgery for pituitary adenomas: current state of the field

verfasst von: Stephanie W. Chang, Daniel A. Donoho, Gabriel Zada

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Differentiation of normal pituitary from abnormal tumor tissue remains a surgical challenge despite improvements in optical visualization technology for pituitary adenoma (PA) surgery. During neurosurgical procedures for other tumor types, 5-aminolevulinic acid (5-ALA) has become a focus of investigation based on its high specificity in differentiating tumor tissue. However, the role of 5-ALA and other optical fluorescent agents in PA surgery remains less clear.

Objective

To perform a systematic review on the use of various optical fluorescent agents in PA surgery.

Method

Using PRISMA guidelines, a systematic literature review to identify reports describing 5-ALA and other optical agents for fluorescence-guided surgery for PA was performed. Eleven research studies met inclusion criteria and were reviewed.

Results

In two studies, 5-ALA was not shown to be effective in aiding PA resection using standard neurosurgical endoscopic/microscopic approaches. 5-ALA photodynamic therapy was evaluated in two in-vitro models with inconsistent results. Intraoperative use of indocyanine green (ICG) concluded with varying results, but showed a tendency towards improved differentiation of functional PA. OTL38 showed potential for intraoperative identification of nonfunctioning PA, particularly in tumors with high folate receptor expression. One study reported clinically useful fluorescence following sodium fluorescein administration.

Conclusion

We conclude that selected optical fluorescent agents, including ICG and folate receptors, are most likely to hold promise for clinical use in differentiating PA from normal tissue.
Literatur
4.
Zurück zum Zitat Dusek T, Kastelan D, Melada A, Baretic M, Skoric Polovina T, Perkovic Z, Giljevic Z, Jelcic J, Paladino J, Korsic M, Aganovic I (2011) Clinical features and therapeutic outcomes of patients with acromegaly: single-center experience. Endocrinol Invest 32:e382–e385. https://doi.org/10.3275/7858 CrossRef Dusek T, Kastelan D, Melada A, Baretic M, Skoric Polovina T, Perkovic Z, Giljevic Z, Jelcic J, Paladino J, Korsic M, Aganovic I (2011) Clinical features and therapeutic outcomes of patients with acromegaly: single-center experience. Endocrinol Invest 32:e382–e385. https://​doi.​org/​10.​3275/​7858 CrossRef
9.
Zurück zum Zitat Biller BMK, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JAH, Boscaro M (2008) Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 93:2454–2462CrossRefPubMedPubMedCentral Biller BMK, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JAH, Boscaro M (2008) Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 93:2454–2462CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Jane JA Jr., Laws ER Jr. (2000) Surgical treatment of pituitary adenomas BTI-Endotext. In: De Groot LJCG, Dungan K et al (ed) MDText.com, Inc., South Dartmouth Jane JA Jr., Laws ER Jr. (2000) Surgical treatment of pituitary adenomas BTI-Endotext. In: De Groot LJCG, Dungan K et al (ed) MDText.com, Inc., South Dartmouth
13.
Zurück zum Zitat Carr SB, Kleinschmidt-DeMasters BK, Kerr JM, Kiseljak-Vassiliades K, Wierman ME, Lillehei KO (2017) Negative surgical exploration in patients with Cushing’s disease: benefit of two-thirds gland resection on remission rate and a review of the literature. J Neurosurg 8:1–8. https://doi.org/10.3171/2017.5.JNS162901 CrossRef Carr SB, Kleinschmidt-DeMasters BK, Kerr JM, Kiseljak-Vassiliades K, Wierman ME, Lillehei KO (2017) Negative surgical exploration in patients with Cushing’s disease: benefit of two-thirds gland resection on remission rate and a review of the literature. J Neurosurg 8:1–8. https://​doi.​org/​10.​3171/​2017.​5.​JNS162901 CrossRef
18.
Zurück zum Zitat Semple PL, Vance ML, Findling J, Laws ER Jr. (2000) Transsphenoidal surgery for Cushing’s disease: outcome in patients with a normal magnetic resonance imaging scan. Neurosurgery 46:553–558CrossRefPubMed Semple PL, Vance ML, Findling J, Laws ER Jr. (2000) Transsphenoidal surgery for Cushing’s disease: outcome in patients with a normal magnetic resonance imaging scan. Neurosurgery 46:553–558CrossRefPubMed
19.
Zurück zum Zitat Abe T, Matsumoto K, Kuwazawa J, Toyoda I, Sasaki K (1998) Headache associated with pituitary adenomas. Headache 38:782–786CrossRefPubMed Abe T, Matsumoto K, Kuwazawa J, Toyoda I, Sasaki K (1998) Headache associated with pituitary adenomas. Headache 38:782–786CrossRefPubMed
20.
Zurück zum Zitat Bengtsson BA, Eden S, Ernest I, Oden A, Sjogren B (1988) Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 223:327–335CrossRefPubMed Bengtsson BA, Eden S, Ernest I, Oden A, Sjogren B (1988) Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 223:327–335CrossRefPubMed
21.
Zurück zum Zitat Etxabe J, Vazquez JA (1994) Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol (Oxf) 40:479–484CrossRef Etxabe J, Vazquez JA (1994) Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol (Oxf) 40:479–484CrossRef
24.
Zurück zum Zitat Nomikos P, Buchfelder M, Fahlbusch R (2005) The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’. Eur J Endocrinol 152:379–387CrossRefPubMed Nomikos P, Buchfelder M, Fahlbusch R (2005) The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’. Eur J Endocrinol 152:379–387CrossRefPubMed
25.
30.
Zurück zum Zitat Verstegen MJT, Tummers QRJG, Schutte PJ, Pereira AM, van Furth WR, van de Velde CJH, Malessy MJA, Vahrmeijer AL (2016) Intraoperative identification of a normal pituitary gland and an adenoma using near-infrared fluorescence imaging and low-dose indocyanine green. Oper Neurosurg 12:260–268. https://doi.org/10.1227/NEU.0000000000001328 CrossRef Verstegen MJT, Tummers QRJG, Schutte PJ, Pereira AM, van Furth WR, van de Velde CJH, Malessy MJA, Vahrmeijer AL (2016) Intraoperative identification of a normal pituitary gland and an adenoma using near-infrared fluorescence imaging and low-dose indocyanine green. Oper Neurosurg 12:260–268. https://​doi.​org/​10.​1227/​NEU.​0000000000001328​ CrossRef
31.
Zurück zum Zitat Cho SS, Zeh R, Pierce JT, Jeon J, Nasrallah M, Adappa ND, Palmer JN, Newman JG, White C, Kharlip J, Snyder P, Low P, Singhal S, Grady MS, Lee JYK (2018) Folate receptor near-infrared optical imaging provides sensitive and specific intraoperative visualization of nonfunctional pituitary adenomas. Oper Neurosurg. https://doi.org/10.1093/ons/opy034 CrossRef Cho SS, Zeh R, Pierce JT, Jeon J, Nasrallah M, Adappa ND, Palmer JN, Newman JG, White C, Kharlip J, Snyder P, Low P, Singhal S, Grady MS, Lee JYK (2018) Folate receptor near-infrared optical imaging provides sensitive and specific intraoperative visualization of nonfunctional pituitary adenomas. Oper Neurosurg. https://​doi.​org/​10.​1093/​ons/​opy034 CrossRef
32.
Zurück zum Zitat Lee JYK, Cho SS, Zeh R, Pierce JT, Martinez-Lage M, Adappa ND, Palmer JN, Newman JG, Learned KO, White C, Kharlip J, Snyder P, Low PS, Singhal S, Grady MS (2018) Folate receptor overexpression can be visualized in real time during pituitary adenoma endoscopic transsphenoidal surgery with near-infrared imaging. J Neurosurg 129:390–403. https://doi.org/10.3171/2017.2.JNS163191 CrossRefPubMed Lee JYK, Cho SS, Zeh R, Pierce JT, Martinez-Lage M, Adappa ND, Palmer JN, Newman JG, Learned KO, White C, Kharlip J, Snyder P, Low PS, Singhal S, Grady MS (2018) Folate receptor overexpression can be visualized in real time during pituitary adenoma endoscopic transsphenoidal surgery with near-infrared imaging. J Neurosurg 129:390–403. https://​doi.​org/​10.​3171/​2017.​2.​JNS163191 CrossRefPubMed
33.
Zurück zum Zitat Shinoda J, Yano H, Yoshimura S, Okumura A, Kaku Y, Iwama T, Sakai N (2003) Fluorescence-guided resection of glioblastoma multiforme by using high-dose fluorescein sodium. Technical note. J Neurosurg 99:597–603CrossRefPubMed Shinoda J, Yano H, Yoshimura S, Okumura A, Kaku Y, Iwama T, Sakai N (2003) Fluorescence-guided resection of glioblastoma multiforme by using high-dose fluorescein sodium. Technical note. J Neurosurg 99:597–603CrossRefPubMed
39.
Zurück zum Zitat Kennedy JC, Pottier RH (1992) Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol 14:275–292CrossRef Kennedy JC, Pottier RH (1992) Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol 14:275–292CrossRef
40.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, Altman DG, The PG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Med 6:e1000097CrossRefPubMedPubMedCentral Moher D, Liberati A, Tetzlaff J, Altman DG, The PG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Med 6:e1000097CrossRefPubMedPubMedCentral
Metadaten
Titel
Use of optical fluorescence agents during surgery for pituitary adenomas: current state of the field
verfasst von
Stephanie W. Chang
Daniel A. Donoho
Gabriel Zada
Publikationsdatum
06.12.2018
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 3/2019
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-018-03062-2

Weitere Artikel der Ausgabe 3/2019

Journal of Neuro-Oncology 3/2019 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.